

STAAR SURGICAL CO  
Form 8-K  
November 17, 2017

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): November 16, 2017**

**STAAR Surgical Company**

**(Exact Name of Registrant as Specified in Charter)**

Delaware

0-11634

95-3797439

<b>(State or Other Jurisdiction of Incorporation)</b>	<b>(Commission File Number)</b>	<b>(I.R.S. Employer Identification No.)</b>
---	-------------------------------------	---

1911 Walker Ave., Monrovia, California 91016  
**(Address of Principal Executive Offices) (Zip Code)**

**Registrant's Telephone Number, Including Area Code 626-303-7902**

Not Applicable

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



**Item 7.01 Regulation FD Disclosure.**

At STAAR Surgical Company's Investor and Analyst Day on November 16, 2017, the Company reported results from 24 patients involved in its feasibility clinical study regarding the performance of the EVO+ Visian ICL with Aspheric (EDOF) Optic to correct or reduce presbyopia. Based on the results from the feasibility clinical study, the Company expects to commence in the first quarter of 2018 its pivotal European clinical study of its EVO+ Visian ICL with Aspheric (EDOF) Optic to correct or reduce presbyopia.

The information furnished herewith pursuant to Item 7.01 of this Current Report shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information in Item 7.01 of this Current Report shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STAAR Surgical Company

November 16, 2017 By: /s/ Caren Mason  
Caren Mason  
President and  
Chief Executive  
Officer